Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study
Abstract Background Plasma aldosterone-to-renin ratio (ARR) is popularly used for screening primary aldosteronism (PA). Some medications, including diuretics, are known to have an effect on ARR and cause false-negative and false-positive results in PA screening. Currently, there are no studies on th...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-11-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12902-020-00656-8 |
| _version_ | 1818928897056571392 |
|---|---|
| author | Toshitaka Sawamura Shigehiro Karashima Satoshi Nagase Hidetaka Nambo Eiko Shimizu Takuya Higashitani Daisuke Aono Azusa Ohbatake Mitsuhiro Kometani Masashi Demura Kenji Furukawa Yoshiyu Takeda Takashi Yoneda |
| author_facet | Toshitaka Sawamura Shigehiro Karashima Satoshi Nagase Hidetaka Nambo Eiko Shimizu Takuya Higashitani Daisuke Aono Azusa Ohbatake Mitsuhiro Kometani Masashi Demura Kenji Furukawa Yoshiyu Takeda Takashi Yoneda |
| author_sort | Toshitaka Sawamura |
| collection | DOAJ |
| description | Abstract Background Plasma aldosterone-to-renin ratio (ARR) is popularly used for screening primary aldosteronism (PA). Some medications, including diuretics, are known to have an effect on ARR and cause false-negative and false-positive results in PA screening. Currently, there are no studies on the effects of sodium–glucose cotransporter-2 (SGLT2) inhibitors, which are known to have diuretic effects, on ARR. We aimed to investigate the effects of SGLT2 inhibitors on ARR. Methods We employed a retrospective design; the study was conducted from April 2016 to December 2018 and carried out in three hospitals. Forty patients with diabetes and hypertension were administered SGLT2 inhibitors. ARR was evaluated before 2 to 6 months after the administration of SGLT2 inhibitors to determine their effects on ARR. Results No significant changes in the levels of ARR (90.9 ± 51.6 vs. 81.4 ± 62.9) were found. Body mass index, diastolic blood pressure, heart rate, fasting plasma glucose, and hemoglobin A1c were significantly decreased by SGLT2 inhibitors. Serum creatinine was significantly increased. Conclusion SGLT2 inhibitor administration yielded minimal effects on ARR and did not increase false-negative results in PA screening in patients with diabetes and hypertension more than 2 months after administration. |
| first_indexed | 2024-12-20T03:36:12Z |
| format | Article |
| id | doaj.art-9a36327561d04eac83323f10dc0b544d |
| institution | Directory Open Access Journal |
| issn | 1472-6823 |
| language | English |
| last_indexed | 2024-12-20T03:36:12Z |
| publishDate | 2020-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj.art-9a36327561d04eac83323f10dc0b544d2022-12-21T19:54:53ZengBMCBMC Endocrine Disorders1472-68232020-11-012011810.1186/s12902-020-00656-8Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational studyToshitaka Sawamura0Shigehiro Karashima1Satoshi Nagase2Hidetaka Nambo3Eiko Shimizu4Takuya Higashitani5Daisuke Aono6Azusa Ohbatake7Mitsuhiro Kometani8Masashi Demura9Kenji Furukawa10Yoshiyu Takeda11Takashi Yoneda12Division of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDepartment of Laboratory Sciences, Faculty of Health Sciences, Kanazawa UniversitySchool of Electrical, Information and Communication Engineering, College of Science and Engineering, Kanazawa UniversityDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDepartment of Hygiene, Kanazawa University Graduate School of MedicineHealth Care Center, Japan Advanced Institute of Science and TechnologyDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineDivision of Endocrine and Diabetes, Department of Internal Medicine, Kanazawa University Graduate School of MedicineAbstract Background Plasma aldosterone-to-renin ratio (ARR) is popularly used for screening primary aldosteronism (PA). Some medications, including diuretics, are known to have an effect on ARR and cause false-negative and false-positive results in PA screening. Currently, there are no studies on the effects of sodium–glucose cotransporter-2 (SGLT2) inhibitors, which are known to have diuretic effects, on ARR. We aimed to investigate the effects of SGLT2 inhibitors on ARR. Methods We employed a retrospective design; the study was conducted from April 2016 to December 2018 and carried out in three hospitals. Forty patients with diabetes and hypertension were administered SGLT2 inhibitors. ARR was evaluated before 2 to 6 months after the administration of SGLT2 inhibitors to determine their effects on ARR. Results No significant changes in the levels of ARR (90.9 ± 51.6 vs. 81.4 ± 62.9) were found. Body mass index, diastolic blood pressure, heart rate, fasting plasma glucose, and hemoglobin A1c were significantly decreased by SGLT2 inhibitors. Serum creatinine was significantly increased. Conclusion SGLT2 inhibitor administration yielded minimal effects on ARR and did not increase false-negative results in PA screening in patients with diabetes and hypertension more than 2 months after administration.https://doi.org/10.1186/s12902-020-00656-8SGLT2 inhibitorAldosterone-to-renin ratioRenin-angiotensin-aldosterone systemPrimary aldosteronismDiabetesHypertension |
| spellingShingle | Toshitaka Sawamura Shigehiro Karashima Satoshi Nagase Hidetaka Nambo Eiko Shimizu Takuya Higashitani Daisuke Aono Azusa Ohbatake Mitsuhiro Kometani Masashi Demura Kenji Furukawa Yoshiyu Takeda Takashi Yoneda Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study BMC Endocrine Disorders SGLT2 inhibitor Aldosterone-to-renin ratio Renin-angiotensin-aldosterone system Primary aldosteronism Diabetes Hypertension |
| title | Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study |
| title_full | Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study |
| title_fullStr | Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study |
| title_full_unstemmed | Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study |
| title_short | Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study |
| title_sort | effect of sodium glucose cotransporter 2 inhibitors on aldosterone to renin ratio in diabetic patients with hypertension a retrospective observational study |
| topic | SGLT2 inhibitor Aldosterone-to-renin ratio Renin-angiotensin-aldosterone system Primary aldosteronism Diabetes Hypertension |
| url | https://doi.org/10.1186/s12902-020-00656-8 |
| work_keys_str_mv | AT toshitakasawamura effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT shigehirokarashima effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT satoshinagase effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT hidetakanambo effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT eikoshimizu effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT takuyahigashitani effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT daisukeaono effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT azusaohbatake effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT mitsuhirokometani effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT masashidemura effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT kenjifurukawa effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT yoshiyutakeda effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy AT takashiyoneda effectofsodiumglucosecotransporter2inhibitorsonaldosteronetoreninratioindiabeticpatientswithhypertensionaretrospectiveobservationalstudy |